TY - JOUR AU - Motzer, R. J. PY - 2014 DA - 2014// TI - Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.0703 DO - 10.1200/JCO.2014.59.0703 ID - Motzer2014 ER - TY - JOUR AU - Topalian, S. L. PY - 2012 DA - 2012// TI - Safety, activity, and immune correlates of anti–PD-1 antibody in cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200690 DO - 10.1056/NEJMoa1200690 ID - Topalian2012 ER - TY - JOUR AU - Motzer, R. J. PY - 2015 DA - 2015// TI - Nivolumab versus everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - JOUR AU - Ruiz-Morales, J. M. AU - Heng, D. Y. PY - 2016 DA - 2016// TI - Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience JO - Ther Adv Urol VL - 8 UR - https://doi.org/10.1177/1756287216663073 DO - 10.1177/1756287216663073 ID - Ruiz-Morales2016 ER - TY - JOUR AU - Molina, A. M. PY - 2014 DA - 2014// TI - A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC) JO - Cancer Chemother Pharmacol VL - 73 UR - https://doi.org/10.1007/s00280-013-2339-y DO - 10.1007/s00280-013-2339-y ID - Molina2014 ER - TY - JOUR AU - Sosman, J. A. AU - Puzanov, I. AU - Atkins, M. B. PY - 2007 DA - 2007// TI - Opportunities and obstacles to combination targeted therapy in renal cell cancer JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-1975 DO - 10.1158/1078-0432.CCR-06-1975 ID - Sosman2007 ER - TY - JOUR AU - Heng, D. Y. C. PY - 2009 DA - 2009// TI - Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study JO - JCO VL - 27 UR - https://doi.org/10.1200/JCO.2008.21.4809 DO - 10.1200/JCO.2008.21.4809 ID - Heng2009 ER - TY - JOUR AU - Heng, D. Y. PY - 2013 DA - 2013// TI - External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study JO - The lancet oncology VL - 14 UR - https://doi.org/10.1016/S1470-2045(12)70559-4 DO - 10.1016/S1470-2045(12)70559-4 ID - Heng2013 ER - TY - JOUR AU - Motzer, R. J. PY - 1999 DA - 1999// TI - Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma JO - J Clin Oncol VL - 17 UR - https://doi.org/10.1200/JCO.1999.17.8.2530 DO - 10.1200/JCO.1999.17.8.2530 ID - Motzer1999 ER - TY - JOUR AU - Hu, K. AU - Lou, L. AU - Ye, J. AU - Zhang, S. PY - 2015 DA - 2015// TI - Prognostic role of the neutrophil–lymphocyte ratio in renal cell carcinoma: a meta-analysis JO - BMJ Open VL - 5 UR - https://doi.org/10.1136/bmjopen-2014-006404 DO - 10.1136/bmjopen-2014-006404 ID - Hu2015 ER - TY - JOUR AU - Baum, Y. S. PY - 2016 DA - 2016// TI - Elevated preoperative neutrophil-to-lymphocyte ratio may be associated with decreased overall survival in patients with metastatic clear cell renal cell carcinoma undergoing cytoreductive nephrectomy JO - Asian Journal of Urology VL - 3 UR - https://doi.org/10.1016/j.ajur.2015.09.004 DO - 10.1016/j.ajur.2015.09.004 ID - Baum2016 ER - TY - JOUR AU - Pichler, M. PY - 2013 DA - 2013// TI - Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients JO - Br J Cancer VL - 108 UR - https://doi.org/10.1038/bjc.2013.28 DO - 10.1038/bjc.2013.28 ID - Pichler2013 ER - TY - JOUR AU - Park, Y. H. AU - Ku, J. H. AU - Kwak, C. AU - Kim, H. H. PY - 2014 DA - 2014// TI - Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy JO - Spring VL - 3 UR - https://doi.org/10.1186/2193-1801-3-243 DO - 10.1186/2193-1801-3-243 ID - Park2014 ER - TY - JOUR AU - Keizman, D. PY - 2012 DA - 2012// TI - The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma JO - Eur J Cancer VL - 48 UR - https://doi.org/10.1016/j.ejca.2011.09.001 DO - 10.1016/j.ejca.2011.09.001 ID - Keizman2012 ER - TY - JOUR AU - Garcia-Donas AU - Rodriguez-Antona, C. AU - Jonasch, E. PY - 2013 DA - 2013// TI - Molecular markers to predict response to therapy JO - Semin Oncol VL - 40 UR - https://doi.org/10.1053/j.seminoncol.2013.05.005 DO - 10.1053/j.seminoncol.2013.05.005 ID - Garcia-Donas2013 ER -